AR095977A1 - Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína - Google Patents

Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína

Info

Publication number
AR095977A1
AR095977A1 ARP140101455A ARP140101455A AR095977A1 AR 095977 A1 AR095977 A1 AR 095977A1 AR P140101455 A ARP140101455 A AR P140101455A AR P140101455 A ARP140101455 A AR P140101455A AR 095977 A1 AR095977 A1 AR 095977A1
Authority
AR
Argentina
Prior art keywords
protein
procedure
formation
increase
pyroglutamic acid
Prior art date
Application number
ARP140101455A
Other languages
English (en)
Inventor
Thorne Barbara
Waugh Stephen
Rose Van Schravendijk Marie
Original Assignee
Mabxience S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabxience S A filed Critical Mabxience S A
Publication of AR095977A1 publication Critical patent/AR095977A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un procedimiento para la conversión de un residuo de glutamina y/o ácido glutámico N-terminal de una proteína en ácido piroglutámico en un procedimiento de purificación.
ARP140101455A 2013-04-04 2014-04-01 Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína AR095977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13162241 2013-04-04

Publications (1)

Publication Number Publication Date
AR095977A1 true AR095977A1 (es) 2015-11-25

Family

ID=48044678

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101455A AR095977A1 (es) 2013-04-04 2014-04-01 Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína

Country Status (18)

Country Link
US (1) US10400042B2 (es)
EP (1) EP2981553A1 (es)
JP (1) JP2016523812A (es)
KR (1) KR20150138273A (es)
CN (1) CN105121469A (es)
AR (1) AR095977A1 (es)
AU (1) AU2014247034B2 (es)
BR (1) BR112015025106A2 (es)
CA (1) CA2907766A1 (es)
EC (1) ECSP15043422A (es)
HK (1) HK1221472A1 (es)
MX (1) MX2015014038A (es)
RU (1) RU2015147187A (es)
SA (1) SA515361251B1 (es)
SG (2) SG11201507815XA (es)
TW (1) TW201444863A (es)
UY (1) UY35517A (es)
WO (1) WO2014161940A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
EP3676280A1 (en) * 2017-08-30 2020-07-08 Fresenius Kabi Deutschland GmbH Method for purifying anti-il-6 receptor antibodies
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN112110983A (zh) * 2019-06-21 2020-12-22 正大天晴药业集团股份有限公司 蛋白质的纯化方法
US11598116B1 (en) 2020-10-01 2023-03-07 Florida Aluminum Systems, Llc Mounting system for separating and connecting fencing slabs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
MXPA06006747A (es) * 2003-12-19 2006-08-18 Novo Nordisk As Procesamiento de peptidos y proteinas.
US20060286629A1 (en) * 2003-12-19 2006-12-21 Norby Inga S N Processing of Peptides and Proteins
ATE548657T1 (de) 2004-07-20 2012-03-15 Symphogen As Prozedur zur strukturellen charakterisierung rekombinanter polyclonaler proteine oder einer polyclonalen zelllinie
KR20070072510A (ko) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
SG175597A1 (en) * 2007-10-30 2011-11-28 Genentech Inc Antibody purification by cation exchange chromatography
EP2435476A4 (en) * 2009-05-27 2013-04-17 Synageva Biopharma Corp ANTIBODIES OBTAINED FROM BIRDS
CN102492040B (zh) 2011-12-29 2014-06-25 嘉和生物药业有限公司 一种抗her2或/和抗her3抗体蛋白的纯化方法

Also Published As

Publication number Publication date
EP2981553A1 (en) 2016-02-10
US20160060349A1 (en) 2016-03-03
HK1221472A1 (zh) 2017-06-02
SG11201507815XA (en) 2015-10-29
AU2014247034B2 (en) 2018-08-23
AU2014247034A1 (en) 2015-10-01
RU2015147187A3 (es) 2018-02-28
UY35517A (es) 2014-10-31
JP2016523812A (ja) 2016-08-12
TW201444863A (zh) 2014-12-01
SG10201708088WA (en) 2017-10-30
RU2015147187A (ru) 2017-05-23
BR112015025106A2 (pt) 2017-10-10
CN105121469A (zh) 2015-12-02
ECSP15043422A (es) 2017-03-31
US10400042B2 (en) 2019-09-03
WO2014161940A1 (en) 2014-10-09
MX2015014038A (es) 2016-06-02
SA515361251B1 (ar) 2018-07-01
KR20150138273A (ko) 2015-12-09
CA2907766A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201792613A1 (ru) Модуляторы cot и способы их применения
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
UY34675A (es) ?proceso y aparato para tratar superficies de metal?.
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
MX2022011225A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
PH12014501453A1 (en) Method of reducing exercise-induced joint pain in non-arthritic mammals
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MY178142A (en) Anti-phf-tau antibodies and their uses
MX2016016886A (es) Anticuerpos anti-axl.
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
CA2905610C (en) Hyaluronic acid derivatives
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
IN2014MU00455A (es)
EA201690856A1 (ru) Применение жирной кислоты таллового масла в связывании токсинов
UY34640A (es) Proceso para preparar cemento, morteros y composiciones, con tratamiento de ultrafinos, y composiciones, productos de cemento, y aplicaciones.
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico
UY34802A (es) ?suspensión acuosa que contiene polímeros adsorbibles sostenibles, un proceso para prepararla y su uso?.

Legal Events

Date Code Title Description
FB Suspension of granting procedure